AU2022271388A1 - Heteroaryl derivative compounds, and uses thereof - Google Patents

Heteroaryl derivative compounds, and uses thereof Download PDF

Info

Publication number
AU2022271388A1
AU2022271388A1 AU2022271388A AU2022271388A AU2022271388A1 AU 2022271388 A1 AU2022271388 A1 AU 2022271388A1 AU 2022271388 A AU2022271388 A AU 2022271388A AU 2022271388 A AU2022271388 A AU 2022271388A AU 2022271388 A1 AU2022271388 A1 AU 2022271388A1
Authority
AU
Australia
Prior art keywords
pyrimidin
amine
phenyl
6alkyl
isoxazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022271388A
Other languages
English (en)
Inventor
Woo Mi DO
Seon Ah Hwang
Hyeon Ho Jeon
Hong Ryul JUNG
Nam Doo Kim
Sung Hwan Kim
Youn Ho Lee
Young Yi Lee
Hee Sun RYU
In Seob Shim
Jung Beom Son
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voronoi Inc
Original Assignee
Voronoi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoi Inc filed Critical Voronoi Inc
Publication of AU2022271388A1 publication Critical patent/AU2022271388A1/en
Assigned to VORONOI INC. reassignment VORONOI INC. Request for Assignment Assignors: VORONOI INC., VORONOIBIO INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022271388A 2021-05-17 2022-05-16 Heteroaryl derivative compounds, and uses thereof Pending AU2022271388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210063733 2021-05-17
KR10-2021-0063733 2021-05-17
PCT/KR2022/006994 WO2022245085A1 (ko) 2021-05-17 2022-05-16 헤테로아릴 유도체 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
AU2022271388A1 true AU2022271388A1 (en) 2022-12-01

Family

ID=84141801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022271388A Pending AU2022271388A1 (en) 2021-05-17 2022-05-16 Heteroaryl derivative compounds, and uses thereof

Country Status (12)

Country Link
US (3) US12037330B2 (cg-RX-API-DMAC7.html)
EP (1) EP4342895A4 (cg-RX-API-DMAC7.html)
JP (1) JP7896880B2 (cg-RX-API-DMAC7.html)
KR (2) KR102607051B1 (cg-RX-API-DMAC7.html)
CN (1) CN115667251A (cg-RX-API-DMAC7.html)
AU (1) AU2022271388A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180295A1 (cg-RX-API-DMAC7.html)
IL (1) IL298474A (cg-RX-API-DMAC7.html)
MX (1) MX2022014887A (cg-RX-API-DMAC7.html)
TW (1) TWI869674B (cg-RX-API-DMAC7.html)
WO (1) WO2022245085A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
JP2020526499A (ja) 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
US11440899B2 (en) 2017-10-17 2022-09-13 Merck Patent Gmbh Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
WO2020235902A1 (ko) * 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20230322753A1 (en) 2020-09-18 2023-10-12 Voronoi Inc. Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient
KR20220085735A (ko) 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
US20240262815A1 (en) 2021-05-07 2024-08-08 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations

Also Published As

Publication number Publication date
US20240317730A1 (en) 2024-09-26
US12534457B2 (en) 2026-01-27
TWI869674B (zh) 2025-01-11
TW202310845A (zh) 2023-03-16
US20240166640A1 (en) 2024-05-23
IL298474A (en) 2023-01-01
CN115667251A (zh) 2023-01-31
US20240025888A1 (en) 2024-01-25
US12037330B2 (en) 2024-07-16
KR20220156453A (ko) 2022-11-25
JP7896880B2 (ja) 2026-07-29
EP4342895A4 (en) 2025-09-10
CA3180295A1 (en) 2022-11-24
BR112022024068A2 (pt) 2023-12-05
EP4342895A1 (en) 2024-03-27
KR20230163335A (ko) 2023-11-30
KR102607051B1 (ko) 2023-11-30
US12528799B2 (en) 2026-01-20
WO2022245085A1 (ko) 2022-11-24
JP2024519626A (ja) 2024-05-21
MX2022014887A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
CN112574235B (zh) 一种ret抑制剂、其药物组合物及其用途
CN112939967B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN113135910A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
WO2020181283A1 (en) Carboxamide-pyrimidine derivatives as shp2 antagonists
IL277518B2 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
JP7663968B2 (ja) Wdr5阻害剤及び調節剤
CA3108676A1 (en) Carboxamides as ubiquitin-specific protease inhibitors
CA3145348A1 (en) Pyrazolone and pyrimidine compound, and preparation method and use therefor
US12534457B2 (en) Heteroaryl derivative compounds, and uses thereof
KR20220090443A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
KR20240041340A (ko) 피롤로피리미딘 유도체 화합물 및 이의 용도
KR20220097305A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
WO2025253326A1 (ko) Kras 저해제로서 신규한 3환 화합물 및 이의 용도
AU2023250757A1 (en) Heteroaryl derivative and use thereof
KR20230153951A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
EA052736B1 (ru) Гетероарильные производные и их применение
HK40108597A (en) Heteroaryl derivative compound and use thereof
RU2831125C1 (ru) Класс конденсированных кольцевых соединений и их получение и применение
HK40087825A (en) Heteroaryl derivative compound and use thereof
US20250368635A1 (en) Heteroaryl derivative compound, and uses thereof
CA3269132A1 (en) Heteroaryl derivative compound, and uses thereof
WO2023187471A1 (en) Heteroaryl derivative compounds, and uses thereof
KR20240133663A (ko) 헤테로아릴 유도체 및 이의 용도
KR20240104016A (ko) 헤테로아릴 유도체 화합물 및 이의 용도

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VORONOI INC.

Free format text: FORMER APPLICANT(S): VORONOI INC.; VORONOIBIO INC.